Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study — CIRCUS II

ST Elevation Acute Myocardial Infarction Clinical Trial

Official title:
Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study

Status Completed

Clinical Trial Summary

Infarct size is a major determinant of vital prognosis after AMI. We recently reported that cyclosporine A, when administered immediately prior to PCI reperfusion, can significantly reduce infarct size in STEMI patients. The CIRCUS study aimed at determining the impact of cyclosporine on the combined incidence of (death, hospitalization for heart failure, LV remodelling) at one year after AMI. However, many patients may display increased adverse LV remodelling beyond year 1 and develop heart failure thereafter. The present CIRCUS II trial aims at examining the 3-year clinical outcome of all patients recruited in the CIRCUS study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Infarction
Myocardial Infarction
ST Elevation Acute Myocardial Infarction
ST Elevation Myocardial Infarction

Clinical Trial Details

NCT number	NCT02934217
Study type	Interventional
Source	Hospices Civils de Lyon
Contact
Status	Completed
Phase	Phase 3
Start date	March 2014
Completion date	June 28, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02151929` - Bioresorbable Vascular Scaffold in Patients With Myocardial Infarction	Phase 4
Completed	`NCT02404376` - COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial	Phase 3
Terminated	`NCT00650975` - ThromboAblation in Acute Myocardial Infarction	Phase 2/Phase 3
Unknown status	`NCT01420614` - RadIal Versus Femoral InvEstigation in ST Elevation Acute Coronary Syndrome	N/A
Completed	`NCT01502774` - Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients	Phase 3